Testing Potassium15 against a placebo for hydration status

Exclusion

• −Allergy, sensitivity, intolerance, or dietary restriction, including dairy sensitivity/intolerance, preventing consumption of investigational product, comparatorControl groupThe group a new treatment is measured against.Read more →/control ingredients, or standardized meal
• −Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
• −Self-reported unstable weight for the past 3 months defined as having gained or lost more than 5% of body weight prior to baselineBaselineYour starting measurements, taken before treatment begins.Read more →
• −Poor venous access as assessed by the QI
• −Unstable metabolic disease or chronic diseases as assessed by the QI
• −Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
• −Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)
• −Type I or Type II diabetes and diabetes insipidus
• −Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
• −History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
• −Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
• −Individuals with an autoimmune disease or are immune compromised as assessed by the QI
• −Self-reported confirmation of blood/bleeding disorders as assessed by the QI
• −Use of prescribed medical cannabinoid products
• −Chronic use of THC products (\>2 times/week). Occasional users will be required to washoutWashout periodA gap with no treatment, so the previous one clears your system.Read more → (3-day washout period) and abstain for the duration of the study period
• −Alcohol intake average of \>2 standard drinks per day as assessed by the QI
• −Alcohol or drug abuse within the last 12 months
• −Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy of the investigational product by altering body water regulation (Sections 7.3.1 and 7.3.2)
• −Blood donation 60 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
• −Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
• −Individuals who are cognitively impaired and/or who are unable to give informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →
• −Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
• −Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
• −Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
• −Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow upFollow-upContinued check-ins after the treatment part is finished.Read more → that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
• −Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period